Lunit Inc.

Lunit Inc. develops deep-learning software that detects cancer earlier and supports precision oncology, spanning radiology screening and digital pathology. The company was founded in 2013 by a group of KAIST researchers led by Anthony Paek, originally under the name CLDI before rebranding to Lunit in 2015, and is headquartered in the Gangnam district of Seoul, South Korea.

Its Lunit INSIGHT line analyzes chest X-rays, mammograms and digital breast tomosynthesis to flag suspected malignancies for radiologists, while the Lunit SCOPE suite reads tumor tissue images to quantify PD-L1 expression and immune phenotypes used in cancer drug development. The products carry FDA clearance and CE marking and are deployed by hospitals, screening centers and pharmaceutical partners across more than 40 countries; Lunit has also worked with GE HealthCare, Philips, Guardant Health and NVIDIA.

Lunit raised over $135 million from private investors before listing on South Korea's KOSDAQ exchange under ticker 328130 in July 2022. Around that time co-founder Anthony Paek moved to executive chairman and Brandon Suh became chief executive. In May 2024 the company completed its roughly $193 million acquisition of New Zealand-based breast-imaging firm Volpara Health Technologies, expanding its US commercial reach and pushing combined headcount past 500 across offices in Seoul, the United States, New Zealand and Japan.